{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:20:46Z","timestamp":1787840446564,"version":"build-2784847793"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hypertension remains a leading cause of cardiovascular and renal morbidity worldwide. In early-stage hypertension, appropriate pharmacological intervention is crucial to prevent target organ damage, especially renal impairment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      A randomized, controlled, open-label study was conducted over 12 weeks at a tertiary care hospital. A total of 120 patients newly diagnosed with Stage 1 hypertension (SBP 140\u2013159 mmHg or DBP 90\u201399 mmHg) were enrolled and equally divided into three groups: Group A (ACE inhibitors), Group B (CCBs), and Group C (beta-blockers). Baseline and post-treatment parameters including systolic and diastolic BP, serum creatinine, and estimated glomerular filtration rate (eGFR) were recorded. Data were analyzed using ANOVA and paired\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      -tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The SBP was reduced by the largest percentage in group A (ACE inhibitors; mean decrease of 16.4+\/- 3.2 mmHg) as well as in group C (CG intervention; mean decrease 16.2+\/- 2.2 mmHg), and the eGFR increased by the largest percentage in group A (ACE inhibitors; mean increase of 5.6+\/- 1.8 mL\/min\/1.73 m 2). Group B (CCBs) had modest reduction in BP (mean SBP lowering of 13.7 + 2.9 mmHg) and little effect on the renal functionality. The beta-blockers (group C) achieved the lowest amount of reduction in SBP (11.2 + 3.1 mmHg) and minimal change in eGFR at mean reduction of 1.4 + 2.1 mL\/minute\/1.73 m 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>ACE inhibitors are more effective in controlling early-stage hypertension and provide additional renal protective benefits compared to CCBs and beta-blockers. These findings support the preferential use of ACE inhibitors in hypertensive patients with early signs of renal function compromise.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jpbs.jpbs_1212_25","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T08:00:15Z","timestamp":1766044815000},"page":"S3141-S3143","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Study on the Efficacy of Different Antihypertensive Classes in Early-Stage Hypertension with Renal Function Consideration"],"prefix":"10.4103","volume":"17","author":[{"given":"Meghna Dipakkumar","family":"Chaudhary","sequence":"first","affiliation":[{"name":"Environmental, Health and Safety Manager, Department of Environment, Health and Safety, Hologic, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchi","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Dr. N.D. Desai Faculty of Medical Science and Research, Dharmsinh Desai University, Nadiad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hetali","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Smt. NHL Municipal Medical College, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Physiology, AIIMS Gorakhpur, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falak","family":"Saiyed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Smt. NHL Municipal Medical College, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huma","family":"Saiyad","sequence":"additional","affiliation":[{"name":"Department of Medicine, B. J. Medical College, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"R1-20251218","doi-asserted-by":"crossref","first-page":"19","DOI":"10.63150\/osjdhs.2025.32","article-title":"Knowledge, attitude, and practice study on cardiovascular disease risk factors in the mangalore community","volume":"1","author":"Bhat","year":"2025","journal-title":"Oral Sphere J Dent Health Sci"},{"key":"R2-20251218","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/j.ajkd.2020.10.006","article-title":"Comparative effectiveness of renin-angiotensin system inhibitors and calcium channel blockers in individuals with advanced CKD: A nationwide observational cohort study","volume":"77","author":"Fu","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"R3-20251218","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-020-01290-3","article-title":"ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: A network meta-analysis of randomised clinical trials","volume":"80","author":"Zhang","year":"2020","journal-title":"Drugs"},{"key":"R4-20251218","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nefroe.2019.02.009","article-title":"Detrimental effect of renin-angiotensin blockade on progression of chronic kidney disease at later stages: A matter of dosage adjustment?","volume":"40","author":"Caravaca-Font\u00e1n","year":"2020","journal-title":"Nefrologia (Engl Ed)"},{"key":"R5-20251218","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s11255-018-1991-x","article-title":"The benefits of angiotensin-converting enzyme inhibitors\/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: A meta-analysis","volume":"50","author":"Pongpanich","year":"2018","journal-title":"Int Urol Nephrol"},{"key":"R6-20251218","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.kint.2023.05.024","article-title":"A nationwide cohort study comparing the effectiveness of diuretics and calcium channel blockers on top of renin-angiotensin system inhibitors on chronic kidney disease progression and mortality","volume":"104","author":"Faucon","year":"2023","journal-title":"Kidney Int"},{"key":"R7-20251218","doi-asserted-by":"crossref","first-page":"e068721","DOI":"10.1136\/bmjopen-2022-068721","article-title":"Long-term comparative effectiveness of antihypertensive monotherapies in primary prevention of cardiovascular events: A population-based retrospective inception cohort study in the Netherlands","volume":"13","author":"Li","year":"2023","journal-title":"BMJ Open"},{"key":"R8-20251218","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/0886022X.2016.1165065","article-title":"Effect of calcium channel blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: Systematic review and meta-analysis","volume":"38","author":"Zhao","year":"2016","journal-title":"Ren Fail"}],"container-title":["Journal of Pharmacy and Bioallied Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_1212_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:22:44Z","timestamp":1787836964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_1212_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":8,"journal-issue":{"issue":"Suppl 4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jpbs.jpbs_1212_25","relation":{},"ISSN":["0976-4879","0975-7406"],"issn-type":[{"value":"0976-4879","type":"print"},{"value":"0975-7406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-07-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}